130 related articles for article (PubMed ID: 34378476)
1. High dose methotrexate containing regimen in pediatric non-metastatic extremity osteosarcoma patients: experience from a tertiary cancer center in India.
Rajeswari B; Guruprasad CS; Nair M; Prasanth VR; Sugath BS; Thankamony P
Pediatr Hematol Oncol; 2022 Apr; 39(3):225-232. PubMed ID: 34378476
[TBL] [Abstract][Full Text] [Related]
2. Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin.
Bacci G; Picci P; Ferrari S; Ruggieri P; Casadei R; Tienghi A; Brach del Prever A; Gherlinzoni F; Mercuri M; Monti C
Cancer; 1993 Dec; 72(11):3227-38. PubMed ID: 8242546
[TBL] [Abstract][Full Text] [Related]
3. Combined pre-operative chemotherapy with intra-arterial cisplatin and continuous intravenous adriamycin for high grade osteosarcoma.
Rha SY; Chung HC; Gong SJ; Shim KY; Ahn JB; Yang WI; Shin KH; Yoo NC; Kim JH; Roh JK; Lee CI; Kim BS
Oncol Rep; 1999; 6(3):631-7. PubMed ID: 10203605
[TBL] [Abstract][Full Text] [Related]
4. Outcomes in non-metastatic treatment naive extremity osteosarcoma patients treated with a novel non-high dosemethotrexate-based, dose-dense combination chemotherapy regimen 'OGS-12'.
Bajpai J; Chandrasekharan A; Talreja V; Simha V; Chandrakanth MV; Rekhi B; Khurana S; Khan A; Vora T; Ghosh J; Banavali SD; Gupta S
Eur J Cancer; 2017 Nov; 85():49-58. PubMed ID: 28888849
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.
Ferrari S; Smeland S; Mercuri M; Bertoni F; Longhi A; Ruggieri P; Alvegard TA; Picci P; Capanna R; Bernini G; Müller C; Tienghi A; Wiebe T; Comandone A; Böhling T; Del Prever AB; Brosjö O; Bacci G; Saeter G;
J Clin Oncol; 2005 Dec; 23(34):8845-52. PubMed ID: 16246977
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant and adjuvant chemotherapy with high-dose ifosfamide, doxorubicin, cisplatin and high-dose methotrexate in non-metastatic osteosarcoma of the extremities: a phase II trial in Japan.
Kudawara I; Aoki Y; Ueda T; Araki N; Naka N; Nakanishi H; Matsumine A; Ieguchi M; Mori S; Myoui A; Kuratsu S; Hashimoto N; Yoshikawa H
J Chemother; 2013 Feb; 25(1):41-8. PubMed ID: 23433444
[TBL] [Abstract][Full Text] [Related]
7. Outcomes in Treatment-Naïve Patients With Metastatic Extremity Osteosarcoma Treated With OGS-12, a Novel Non-High-Dose Methotrexate-Based, Dose-Dense Combination Chemotherapy, in a Tertiary Care Cancer Center.
Bajpai J; Chandrasekharan A; Simha V; Talreja V; Karpe A; Pandey N; Singh A; Rekhi B; Vora T; Ghosh J; Banavali S; Gupta S
J Glob Oncol; 2018 Sep; 4():1-10. PubMed ID: 30241240
[TBL] [Abstract][Full Text] [Related]
8. Highly effective reduced toxicity dose-intensive pilot protocol for non-metastatic limb osteogenic sarcoma (SCOS 89).
Shkalim-Zemer V; Ash S; Toledano H; Kollender Y; Issakov J; Yaniv I; Cohen IJ
Cancer Chemother Pharmacol; 2015 Nov; 76(5):909-16. PubMed ID: 26365289
[TBL] [Abstract][Full Text] [Related]
9. Nonmetastatic osteosarcoma of the extremity. Neoadjuvant chemotherapy with methotrexate, cisplatin, doxorubicin and ifosfamide. An Italian Sarcoma Group study (ISG/OS-Oss).
Ferrari S; Meazza C; Palmerini E; Tamburini A; Fagioli F; Cozza R; Ferraresi V; Bisogno G; Mascarin M; Cefalo G; Manfrini M; Capanna R; Biagini R; Donati D; Picci P
Tumori; 2014; 100(6):612-9. PubMed ID: 25688494
[TBL] [Abstract][Full Text] [Related]
10. IAP Chemotherapy Regimen Is a Viable and Cost-effective Option in Children and Adolescents With Osteosarcoma: A Comparative Analysis With MAP Regimen on Toxicity and Survival.
Verma P; Jain S; Kapoor G; Tripathi R; Sharma P; Doval DC
J Pediatr Hematol Oncol; 2021 May; 43(4):e466-e471. PubMed ID: 32925402
[TBL] [Abstract][Full Text] [Related]
11. Experience of pediatric osteosarcoma of the extremity at a single institution in Taiwan: prognostic factors and impact on survival.
Hung GY; Yen HJ; Yen CC; Chen WM; Chen PC; Wu HT; Chiou HJ; Chang WH; Hsu HE
Ann Surg Oncol; 2015 Apr; 22(4):1080-7. PubMed ID: 25323470
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemotherapy for osteosarcoma of the extremities with synchronous lung metastases: treatment with cisplatin, adriamycin and high dose of methotrexate and ifosfamide.
Bacci G; Briccoli A; Ferrari S; Saeter G; Donati D; Longhi A; Manfrini M; Bertoni F; Rimondini S; Monti C; Forni C
Oncol Rep; 2000; 7(2):339-46. PubMed ID: 10671683
[TBL] [Abstract][Full Text] [Related]
13. High dose ifosfamide in combination with high dose methotrexate, adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group pilot study.
Bacci G; Ferrari S; Longhi A; Picci P; Mercuri M; Alvegard TA; Saeter G; Donati D; Manfrini M; Lari S; Briccoli A; Forni C;
J Chemother; 2002 Apr; 14(2):198-206. PubMed ID: 12017378
[TBL] [Abstract][Full Text] [Related]
14. Frontline treatment of localized osteosarcoma without methotrexate: results of the St. Jude Children's Research Hospital OS99 trial.
Daw NC; Neel MD; Rao BN; Billups CA; Wu J; Jenkins JJ; Quintana J; Luchtman-Jones L; Villarroel M; Santana VM
Cancer; 2011 Jun; 117(12):2770-8. PubMed ID: 21656756
[TBL] [Abstract][Full Text] [Related]
15. Pirarubicin versus doxorubicin in neoadjuvant/adjuvant chemotherapy for stage IIB limb high-grade osteosarcoma: does the analog matter?
Yu W; Tang L; Lin F; Yao Y; Shen Z
Med Oncol; 2015 Jan; 32(1):307. PubMed ID: 25432694
[TBL] [Abstract][Full Text] [Related]
16. Delayed methotrexate clearance in osteosarcoma patients treated with multiagent regimens of neoadjuvant chemotherapy.
Bacci G; Ferrari S; Longhi A; Forni C; Loro L; Beghelli C; Tremosini M; Versari M
Oncol Rep; 2003; 10(4):851-7. PubMed ID: 12792734
[TBL] [Abstract][Full Text] [Related]
17. Comparative outcome of Thai pediatric osteosarcoma treated with two protocols: the role of high-dose methotrexate (HDMTX) in a single institute experience.
Choeyprasert W; Pakakasama S; Sirachainan N; Songdej D; Chuansumrit A; Anurathapan U; Hongeng S; Nartthanarung A
Asian Pac J Cancer Prev; 2014; 15(22):9823-9. PubMed ID: 25520112
[TBL] [Abstract][Full Text] [Related]
18. Presurgical window of carboplatin and surgery and multidrug chemotherapy for the treatment of newly diagnosed metastatic or unresectable osteosarcoma: Pediatric Oncology Group Trial.
Ferguson WS; Harris MB; Goorin AM; Gebhardt MC; Link MP; Shochat SJ; Siegal GP; Devidas M; Grier HE
J Pediatr Hematol Oncol; 2001; 23(6):340-8. PubMed ID: 11563767
[TBL] [Abstract][Full Text] [Related]
19. Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the extremities. The Istituto Rizzoli Experience in 127 patients treated preoperatively with intravenous methotrexate (high versus moderate doses) and intraarterial cisplatin.
Bacci G; Picci P; Ruggieri P; Mercuri M; Avella M; Capanna R; Brach Del Prever A; Mancini A; Gherlinzoni F; Padovani G
Cancer; 1990 Jun; 65(11):2539-53. PubMed ID: 2337871
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy for osteosarcoma without high-dose methotrexate: a 12-year follow-up on 53 patients.
Tunn PU; Reichardt P
Onkologie; 2007 May; 30(5):228-32. PubMed ID: 17460416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
